Adaptive CEO joins distinguished panel at Genomics 2.0 Conference to Discuss Company’s Pipeline of Cancer Diagnostics


Adaptive announced today that Chad Robins, its Founder and Chief Executive Officer, is participating in a panel discussion this morning at the prestigious Genomics 2.0 Conference in Park City, Utah. The panel, entitled “Changing the Game in Oncology,” includes other industry notables Randy Scott, CEO of Invitae,  Steven Kafka, COO of Foundation Medicine, and Ronnie Andrews, Division President at Thermo Fisher.

Veteran Microsoft Executive and Distinguished Engineer, Sean Nolan, joins Adaptive Biotechnologies as Chief Technology Officer


Adaptive is pleased to announce the appointment of Sean Nolan as Chief Technology Officer and the newest member of the Company’s expanding Executive Leadership Team.  Mr. Nolan’s hire, the second management hire this month, represents Adaptive’s continued commitment to incorporating state-of-the-art data solutions into its suite of immunosequencing products and services.

Adaptive in Seattle Times


Adaptive Biotechnologies, a Seattle startup that focuses on scouring the genetic makeup of the immune system to help fight cancer and other diseases, said Monday it has raised an eye-popping $105 million in funding to boost its research and commercial efforts. Read full article at Times Website

Adaptive Biotechnologies Announces Completion of Series C and Series D Financing Rounds Through a $105 million Private Investment from Viking Global Investors

Original Founders of Adaptive

Adaptive announced today the completion of the Company’s Series C financing round and the completion of a newly created Series D round with a $105 million investment from Viking Global Investors.  This investment will enable the Company to expand globally its preeminent immunosequencing research platform and downstream validated clinical diagnostic products.